If the 911 addressing coordinator cannot be found on the county website, then you can contact the non-emergency number for the county to ask for the appropriate addressing authority.
DIRECTIONS TO HOME UPDATE
Most counties have a 911 addressing coordinator that may be found on your county's website that is responsible to update information on address changes or to resolve address issues. Some map makers, such as Google, use the National Address Database to update the address data found in navigation devices, apps, and online maps. states ( view list at ) and select counties. The National Address Database is a composite of authoritative addressing information submitted by participating U.S. By working with them, you should be able to correct how your address appears on maps used by 911 call responders and your post office, and possibly in the National Address Database. Your local county or municipality is responsible for maintaining your authoritative street address. An internet search for "business location data management" should point you in the right direction.Ģ Contact your local addressing authority If you are a business, consider hiring a firm that can correct and maintain your location information across multiple mapping systems on your behalf. We list them for information only and do not endorse any non-governmental products, services, or views.
DIRECTIONS TO HOME REGISTRATION
The websites above are not run by the government and may require registration and/or browser plug-ins. Apple Business Register - Places on Maps.Google Maps: Report an error on the mapĬorrects Lyft and other mobile apps, social networks, and many car navigation systems.To reach the most GPS users, we recommend reporting the same problem at each of these websites. Please be aware that we do not take any responsibility for your accessing such information that may not comply with any legal process, regulation, registration, or usage in the country of your origin.Visit the following websites to report the mapping error directly to the companies and organizations that maintain digital maps. Additionally, this website contains information on products that is targeted to many different audiences and could contain product details or information otherwise not accessible or valid in your country. If you do not agree to these terms, do not use the website.
By accessing, browsing and/or using this website, you acknowledge that you have read, understood, and agree to be bound by Quidel’s Website Terms and Conditions, Privacy Policy and to comply with all applicable laws and regulations. No use of any Quidel trademark, trade name, or trade dress in this site may be made without the prior written authorization of Quidel, except to identify the product or services of the company. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Quidel, its subsidiaries or affiliates. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.Ĭopyright ©2021 Quidel Corporation. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. *In the USA, this product has not been FDA cleared or approved but has been authorized by FDA under an Emergency Use Authorization. This test is authorized for nonprescription home use with self-collected (unobserved) direct anterior nasal (NS) swab specimens from individuals aged 14 years and older or with adult-collected anterior NS samples from individuals aged 2 years or older.
DIRECTIONS TO HOME SERIAL
Serial testing should be performed in individuals with negative results at least twice over three days (with 48 hours between tests) for symptomatic individuals and three times over five days (with at least 48 hours between tests) for asymptomatic individuals.
The QuickVue At-Home OTC COVID-19 Test is intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19.
0 kommentar(er)
